Navigation Links
Healionics Corporation Completes Series A Financing
Date:1/29/2008

REDMOND, Wash., Jan. 29 /PRNewswire/ -- Healionics Corporation, a provider of tissue regeneration and device biointegration solutions to healthcare manufacturers, today announced that it has raised $1.7 million in a Series A financing. The financing was led by individual investors including Carl Lombardi, former CEO of SpaceLabs Medical and Sam Naficy, M.D., Medical Director of Naficy Plastic Surgery & Rejuvenation Center.

"We are pleased to secure this financing, which provides recognition of our technology platform and allows Healionics to continue expanding the potential of STAR materials to enhance current and next generation medical devices," said Rob Brown, Chief Executive Officer of Healionics. "These funds will be used specifically to scale up the STAR material manufacturing process, to expand and accelerate preclinical studies of STAR materials and to advance our business development activities."

Healionics' propriety STAR Material -- Sphere Templated Angiogenic Regenerative Material -- is specifically engineered to enhance biointegration and promote healing. Described as the 'Gore-Tex(TM) of biomaterials,' STAR is designed to enable the biocompatibility of a wide range of medical devices that are implanted into the body.

"Healionics has a very promising technology that offers widespread opportunities in a rapidly expanding cosmetic market," said Sam Naficy, M.D. "It is this versatility and expansiveness that make Healionics a very attractive business model, and I look forward to the future advancement of this Company."

Healionics was formed in March 2007. To date, Healionics has entered into multiple agreements for the advancement of its STAR(TM) material into various market applications including diabetes, wound care and infusion therapy.

About Healionics Corporation

Healionics is a privately held biomaterials company whose mission is to be the leading partner of tissue regeneration and device biointegratio
'/>"/>

SOURCE Healionics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Healionics Corporation Announces Partnership to Develop and Distribute STARcuff(TM)
2. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
5. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
6. BioElectronics Corporation Announces Singapore and Malaysia Sales
7. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
8. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
9. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
10. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
11. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... ... R-Biopharm is proud to announce the RIDASCREEN® Gliadin Competitive ... been accepted by AOAC International as Official First Action method. The AOAC Official ... R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially celiac toxic ...
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
(Date:7/30/2015)... USA (PRWEB) , ... July 30, 2015 , ... ... microsystems, has appointed Francois Vieillard as Sales & Marketing Director. , With ... Francois Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4
... N.Y., March 20 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... pre-clinical program in Hepatitis C focused on the ... Inc. Presidio,is a private biotechnology company focused on ... backed by some of the,most prominent investors in ...
... Corporation, a leading,provider of fully integrated imaging ... of its real-time patient and resource,scheduler software, ... staff, rooms with drag and drop ease,delivering ... ROI., A free CardioSchedule Information Kit ...
... March 20 Amsterdam Molecular,Therapeutics (Euronext: AMT), a ... announced that AMT,s Supervisory Board has decided to ... Board at its Annual,General Meeting of shareholders on ... of TomTom (Euronext Amsterdam: TOM2), and has been,instrumental ...
Cached Biology Technology:XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals 2XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals 3XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals 4LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems 2Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board 2Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board 3
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... A major initiative to create alternative nesting sites for the ... help protect juvenile salmon and steelhead in the Columbia River ... nesting site at Crump Lake in southern Oregon, which was just ... more than 135 nesting pairs of Caspian terns, as well as ...
... called for Europe to invest more funds into the study ... role in the function of human cells and which are ... to Alzheimer,s. Common lipids such as cholesterol are known ... cells and tissues, but human cells contain thousands of different ...
... Belfast is appealing for help from the public in looking ... Activities such as aquaculture, shipping and recreational boating have led ... Now Queen,s is attempting to find out exactly where and how ... this it is asking for help from the public to record ...
Cached Biology News:Project succeeding to relocate Caspian terns 2Project succeeding to relocate Caspian terns 3Project succeeding to relocate Caspian terns 4Project succeeding to relocate Caspian terns 5Project succeeding to relocate Caspian terns 6Europe-wide investment in lipid research will help tackle disease, says new report 2Queen's marine biologist investigates aliens beneath the waves 2
...
... antibody-based immunoaffinity matrices, such as Sepharose ... without compromising antigen-antibody reactivity, the need ... has precluded the application of these ... CHEMICON Re-Blot Plus Western Blot Mild ...
Applications: Western blotting ...
Applications: Western blotting ...
Biology Products: